EDISON EQUITY RESEARCH - AETERNA ZENTARIS
27 August 2014 - 2:28AM
InvestorsHub NewsWire
Edison Investment Research:
Aeterna
Zentaris - Nearing transition to a commercial
story
Aeterna Zentaris is poised to transition to a
commercial entity in 2015. Macrilen has an FDA PDUFA date of 5
November in the evaluation of adult growth hormone deficiency
(AGHD), a category currently dominated by insulin tolerance tests.
Aeterna plans to launch Macrilen in January 2015, if approved. With
$39m in cash at 30 June 2014, Aeterna is funded through the
reporting of key interim data from its Phase III study of
zoptarelin doxorubicin for advanced endometrial cancer, expected
near mid-2015.
Aeterna Zentaris is a specialty biopharmaceutical
firm developing therapies in oncology and endocrinology. Its lead
compounds include zoptarelin doxorubicin, in Phase III trials for
endometrial cancer, and Macrilen (macimorelin), under NDA review
for adult growth hormone deficiency
assessment.
Follow the link to view the full report: http://www.edisoninvestmentresearch.com/research/report/aeterna-zentaris2
Click here to view all of Edison
Investment Research's published reports.
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2024 to May 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From May 2023 to May 2024